S-551, a class III anti-arrhythmic agent, with a pyrimidinedione structure, inhibits the rapiddelayed rectifier K + currents (IKr) at therapeutic concentrations of 1-10 mol/L 1 and, furthermore, inhibits several other K + channels at concentrations above 10 mol/L. [2] [3] [4] [5] [6] The blocking of K + channels can prolong the duration of the action potential 4,7 and consequently prolong the myocardial refractory period, 4,6-9 suggesting that the chief anti-arrhythmic action of nifekalant comes from the suppressive action against re-entrant arrhythmias. 7,9 By this blocking of K + channels, nifekalant exerts a clinically potent suppressive action against ventricular tachyarrhythmias. [9] [10] [11] To achieve optimal anti-arrhythmic effects with drugs, the clinician needs to avoid the pro-arrhythmic actions of the drug. In the case of nifekalant, one may anticipate that the drug will increase the cellular Ca 2+ load because of the prolongation of the action potential and thereby induce triggered premature beats and triggered arrhythmias. 12, 13 Triggered rhythms caused by propagating Ca 2+ waves in non-uniform cardiac muscle are a well-established experimental model, 12 which is suitable to investigate this question regarding nifekalant. These Ca 2+ waves, 14 which have Circulation Journal Vol.69, June 2005 lines for the care and use of laboratory animals of Tohoku University. Trabeculae were obtained as previously described. 14,17 Sprague -Dawley rats (250-300 g) were anesthetized and hearts were excised. Sixteen trabeculae (length = Circ J 2005; 69: 739 -745
been observed as a propagation of regional increases in intracellular Ca 2+ ([Ca 2+ ]i) with aftercontractions and delayed afterdepolarizations (DADs), 12 start from damaged regions within both rat ventricular 15 and human atrial cardiac muscle. 12 The velocity of Ca 2+ waves ranges from 0.34 to 5.47 mm/s, 12 depending on both [Ca 2+ ]i and Ca 2+ loading in the sarcoplasmic reticulum (SR). 14 The acceleration of Ca 2+ waves caused by the increase in the cellular Ca 2+ loading can increase the amplitude of DADs 16 and finally induce triggered arrhythmias. 17 Such triggered arrhythmias from DADs have been reported to play an important role in the occurrence of tachyarrhythmias in heart diseases such as heart failure, 18, 19 cardiac hypertrophy 20 and digitalis intoxication.
Therefore, in this study, we investigated: (i) the effect of nifekalant on the action potential, Ca 2+ transient, and developed force of rat myocardium to determine whether nifekalant increases muscle contraction with an increase in cellular Ca 2+ loading; and (ii) the effect of nifekalant on the velocity of Ca 2+ waves and aftercontractions to evaluate whether nifekalant can affect triggered arrhythmias as well as re-entrant arrhythmias.
Methods

Dissection and Mounting of Rat Ventricular Trabeculae
The experiments were performed according to the guide-1.74±0.12 mm, width =429±54 m, thickness =108±7 m) were dissected from 16 right ventricles and equilibrated at 0.5 Hz stimuli through parallel platinum electrodes in a bath with 5 ms pulses 50% above the threshold ([Ca 2+ ]o = 0.7 mmol/L) at room temperature. Force was measured by using a silicon semiconductor strain gauge and expressed as stress after normalizing for the cross sectional area of the muscle in slack conditions. Sarcomere length (SL) was measured by using laser diffraction techniques.
Membrane Potential Measurements
The membrane potential was measured by using ultracompliant glass microelectrodes as previously described. 15, 17 Briefly, flexible, stepped electrodes drawn with a glass microelectrode puller (Narishige, Japan) were filled with 3 mol/L KCl and connected to a high input-impedance amplifier (MEZ-8201, Nihon Koden, Japan). The center of a trabecula was impaled. Long-term stable measurements were possible using these electrodes without causing local damage during contraction. To estimate the duration of the action potential, the duration of the action potential at 90% repolarization (APD90) was measured.
Fura-2 Loading and Measurement of Fluorescence
[Ca 2+ ]i was measured as previously described. 14, 17 Fura-2 pentapotassium salt was microinjected electrophoretically into one cell and allowed to spread uniformly throughout the trabeculae via gap junctions. The epifluorescence of fura-2 from the trabecula at excitation wavelengths of 340 and 380 nm was measured at 510 nm by a photomultiplier tube (PMT; E1341 with a C1556 socket, Hamamatsu, Japan). The signal from the PMT was stored (RD-130TE DAT Data Recorder, TEAC, Japan) and used for the calculation of [Ca 2+ ]i. Alternatively, the fluorescent image of the trabecula at excitation wavelengths of 360 and 380 nm was recorded by a CCD camera coupled to a 2-stage image intensifier (Hamamatsu ICCD Video Camera C2400-89, Hamamatsu, Japan) through a 510 bandpass filter. The images were recorded with a videocassette recorder (VCR) for off line analysis.
Analysis of a Fura-2 Image
Fura-2 fluorescence images recorded at 30 frames/s on the VCR were analyzed as previously described. 14, 17 Briefly, fluorescence data of each video frame were digitized with an 8-bit analog-digital converter and stored in a frame buffer memory of 512×512 pixels (ALL-IN-WONDER128 (32MB), ATI, Canada). Therefore, in our optical system, 1 pixel corresponded to 2.55×2.55 m in the image plane. For analysis of the image, we first set a region of interest (ROI) of 512×25 pixels horizontally along the long axis of the fluorescence image of the trabeculae, then the intensity profiles of the fluorescence from the averaged intensity value of each vertical line of pixels within the ROI was obtained, which was then followed by the elimination of high frequency noise from the intensity profile using a low-pass finite impulse response filter (MATLAB) with a cut-off frequency of 5 pixels. After subtraction of the autofluorescence, the ratio of the fluorescence at 360 nm to that at 380 nm excitation light at each point on the intensity profiles was then calculated, and this was then followed by the calculation for [Ca 2+ ]i only for the centrally located 300 pixels of the ROI where the muscles were intact and the propagation of Ca 2+ waves along trabeculae was observed.
To calculate the velocity of Ca 2+ waves, the peak time and the peak amplitude of a Ca 2+ transient during the Ca 2+ wave at each position along the long axis of trabeculae was first observed and then the peak position against the peak time during the Ca 2+ wave was plotted. The velocity was calculated from the slope of the fitted line to the plot when regression analysis showed a linear relationship (r ≥0.9), as described previously. 17 
Rapid Cooling Contracture
Two perfusion lines leading to the bath inlet were connected to a DC torque motor driven by voltage commands from a personal computer via a 12 bit D/A converter (T-IFPC9 04120A-N, T.S.K., Japan). In response to the voltage command, one of the perfusion lines, which was filled with a warm solution (~24°C), was instantly replaced by the other perfusion line, which was jacketed with ethylene glycolwater (-5°C). Switching from a warm solution to a cold solution cooled the muscle surface to below 1°C within 1 s at the flow rate of ~20 ml/min and maintained the bath temperature at ~1°C during steady cold perfusion (Fig 1) . The time courses of cooling were sufficiently rapid to produce reproducible rapid cooling contractures (RCCs). By using the amplitudes of the RCCs, the estimated Ca 2+ content in SR could be determined. 21 
Experimental Protocol
The effect of nifekalant (Nihon Schering K.K., Japan) on action potentials, Ca 2+ transients and the developed forces in 6 trabeculae and on RCCs in 5 trabeculae was observed. Trabeculae were stimulated electrically at 0.5 Hz and superfused with a K-H solution containing nifekalant ([Ca 2+ ]o = 0.7 mmol/L, temperature =26.0±0.2°C, SL =2.1 m). At first, 1 and 10 mol/L nifekalant was used because the therapeutic concentration ranges from 1 to 10 mol/L (1); then 250 mol/L nifekalant was used to determine the effect of it on cardiac muscle at an extremely high concentration. [2] [3] [4] [5] [6] All measurements were completed within 20 min.
The effects of nifekalant on the velocity of Ca 2+ waves and the accompanying aftercontractions were studied in 5 trabeculae. In order to induce Ca 2+ waves, trains of electrical stimuli at an interval of 500 ms were applied for 7.5 s at a [Ca 2+ ]o of 1.0 mmol/L. This stimulus protocol was repeated every 15 s. [Ca 2+ ]o was then increased in steps of 0.2-0.3 mmol/L until a Ca 2+ wave appeared. 14, 17 The measurement of developed force, [Ca 2+ ]i, and the membrane potential was started when Ca 2+ waves had reached a steady state ([Ca 2+ ]o =1.8±0.1 mmol/L, temperature =22.3± 0.5°C, SL =2.1 m). When the Ca 2+ waves were reproducible, trabeculae were superfused with a K-H solution containing 10 and 250 mol/L nifekalant. After the superfusion with nifekalant, the developed force by trains of electrical stimuli reached a new steady level within 5 min; the developed force, [Ca 2+ ]i, and the membrane potential were then measured again. The peak force of the aftercontraction (PeakAC) and the time between the last stimulus and the PeakAC (TimeAC) was also measured. All measurements were completed within 30 min.
Statistical Analysis
All measurements were expressed as mean ± SEM. Statistical analysis was performed by using ANOVA and the paired Student's t-test as appropriate. Values of p<0.05 were considered to be significant. Fig 2 shows the effect of nifekalant on the action potentials, Ca 2+ transients, developed forces, and the amplitude of RCCs at 0.5 Hz electrical stimulation. The left panel of Fig 2A shows an example of changes in the action potential duration. In the absence of nifekalant, the action potential showed a short plateau phase and a slow final repolarization phase, which was typical for rat trabeculae. 17 After the addition of 10 and 250 mol/L nifekalant, APD90 increased by 12 and 17%, respectively. The summed data in the right panel show that nifekalant significantly increased APD90. In Fig 2B-D , nifekalant significantly increased the peak [Ca 2+ ]i, the developed force, and the amplitude of RCCs depending on the concentration.
Results
We have previously reported that the cellular Ca 2+ level can determine the velocity of Ca 2+ waves. 14 ing the twitch contraction induced by the last stimulus of a train and the following aftercontraction. The addition of 250 mol/L nifekalant increased the velocity of Ca 2+ waves to 3.6 mm/s with the earlier and higher occurrence of aftercontractions ( Fig 3B) . Fig 4 shows the summed data obtained from the 5 trabeculae. Nifekalant significantly increased the velocity of Ca 2+ waves and facilitated the occurrence of aftercontractions depending on the concentration.
It has been reported that Ca 2+ waves propagate along trabeculae, accompanying aftercontractions and DADs, 17 and that the amplitudes of DADs correlate linearly with the velocity of Ca 2+ waves 16 as well as the amplitudes of aftercontractions. 15 Thus, we observed the effect of nifekalant on DADs as shown in Fig 5. Nifekalant facilitated the occur-rence of both aftercontractions and DADs in a concentration-dependent manner.
Discussion
This is the first study to evaluate the effect of nifekalant, a class III anti-arrhythmic agent, on the velocity of Ca 2+ waves by direct measurement of the spatial and temporal properties of Ca 2+ changes in a cardiac multicellular preparation. With the increase in the cellular Ca 2+ loading because of the prolongation of the action potential, nifekalant, even at therapeutic concentrations, can increase muscle contraction, but may accelerate Ca 2+ waves with the enhancement of aftercontractions, causing triggered arrhythmias under Ca 2+ -overloaded conditions, as will be discussed below.
Effect of Nifekalant on Cellular Ca 2+ Loading
Rat ventricular muscle possesses the rapid-delayed rectifier IKr. 22 Nifekalant inhibits the IKr at therapeutic concentrations between 1 and 10 mol/L. 1 At concentrations above 10 mol/L, nifekalant inhibits several other channels, including Na + current (IC50 =292±20 mol/L), 2 the muscarinic acetylcholine receptor-operated K + current (atrial cells, IC50= 11.4 mol/L), 3 the Na + -activated K + current (≥300 mol/L), 5 the inward rectifier K + current (≥10 mol/L), 4 the transient outward current (≥10 mol/L), 4 and the ATP-dependent K + channel (IC50 =980 mol/L). 6 Thus, we assume that the prolongation of the action potential at 1 and 10 mol/L nifekalant mainly resulted from the blocking action of IKr and that the further prolongation of the action potential at 250 mol/L nifekalant resulted from the decrease in the outward currents caused by the blocking of the other K + channels.
Interventions that prolong the action potential have been known to increase the muscle contraction. [22] [23] [24] Studies using cardiac muscle have shown that the inhibition of repolarizing K + currents 25 and the stimulation of 1-, 26 1-, and 2-adrenoceptors 27 can produce an increase in muscle contraction as well as a prolongation of the action potential in the majority of mammalian species, including humans. 28 Although this correlation between the duration of the action potential and the contractility was also observed in the present study, the mechanisms for the positive inotropic effect by nifekalant have not yet been established. Possible mechanisms include increased Ca 2+ influx through voltagedependent Ca 2+ channels, 29 altered Ca 2+ extrusion by the Na + -Ca 2+ exchanger, 30 or a combination of both, 31 which could directly alter the Ca 2+ supply to the myofilaments or indirectly alter it by changing the SR Ca 2+ loading. 32 Fig 2 shows that nifekalant increased the amplitude of RCCs as well as the APD90, depending on the concentration, suggesting that the prolongation of the action potential may indirectly increase the cellular Ca 2+ loading, especially in SR, which caused the positive inotropic effect. Such a positive inotropic effect has been observed in most other class III anti-arrhythmic agents. [33] [34] [35] 
Effect of Nifekalant on Ca 2+ Waves
The increase in cellular Ca 2+ loading by nifekalant, as described above, may cause an acceleration of Ca 2+ waves under Ca 2+ -overloaded conditions because, as we have reported previously, cellular Ca 2+ loading can determine the velocity of Ca 2+ waves. 14 The acceleration of Ca 2+ waves as well as the enhancement of aftercontractions by nifekalant (Figs 3,4) can facilitate the occurrence of DADs, which is shown in Fig 5, because the velocity of Ca 2+ waves 16 as well as the amplitudes of aftercontractions 15 have been reported to correlate linearly with the amplitudes of DADs. In addition, the amount of Ca 2+ released from the SR during the propagation of Ca 2+ waves can determine the amplitude of DADs as a result of electrogenic Na + -Ca 2+ exchange and/or Ca 2+ -activated non-selective cation currents. 12 Therefore, we assume that the acceleration of Ca 2+ waves by nifekalant can increase the amplitude of DADs because of the secondary increase in cellular Ca 2+ loading 36, 37 and thereby induce triggered arrhythmias. These observations are consistent with reports that class III anti-arrhythmic agents such as E-4031 and dofetilide can consistently increase the amplitude of DADs and can occasionally cause triggered action potentials. 38 Arrhythmias can occur because of abnormalities in impulse initiation (abnormal automaticity or triggered activity), impulse conduction (re-entry) or a combination of the 2 abnormalities. In failing rabbit and human hearts, 3-dimensional cardiac mapping has demonstrated that spontaneous and induced ventricular tachyarrhythmias are initiated by a focal non-re-entrant mechanism 39,40 that may be caused by triggered activity from DADs. 18, 19 Moreover, such tachyarrhythmias may occur in digitalis intoxication and cardiac hypertrophy by the triggered mechanism caused by Ca 2+ overload. 20 In these cases, it is possible that nifekalant may be pro-arrhythmic if the patient is sensitive to this effect, because nifekalant can increase the amplitude of DADs as shown in Fig 5. In contrast, it has been reported that nifekalant can prolong the myocardial refractory period, 4, [6] [7] [8] [9] 41 suggesting that nifekalant exerts a suppressive action against re-entrant arrhythmias, 7,9 although the prolongation of repolarization can be associated with pro-arrhythmic actions inducing torsades de pointes tachycardia or ventricular fibrillation because of early afterdepolarizations. 42 Therefore, when we use nifekalant and other class III anti-arrhythmic agents to treat patients with tachyarrhythmias, we should pay careful attention to the basic mechanisms underlying the arrhythmias.
